Biotech | February 17, 2022
Kato wins USFDA approval for studies in retinal disorder
Resolv ER may remedy leading causes of blindness in adults
Resolv ER may remedy leading causes of blindness in adults
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The stability is led by healthy demand in the domestic and emerging markets
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Subscribe To Our Newsletter & Stay Updated
